In two-month post-treatment muscle biopsies, clinical trial participants showed a mean of 51% beta-sarcoglycan (beta-SG) positive fibers, as measured by ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot FDA News Management Comments

Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy CompanyFebruary 28, 2019 6:51 AM Sarepta Therapeutics (SRPT) PT Raised to $213 at CowenFebruary 28, 2019 6:21 AM Sarepta Therapeutics (SRPT) Tops Q4 EPS by 19c, Revenues MissFebruary 27, 2019 4:15 PM Sarepta (SRPT) Phase I/IIa MYO-101 Trial Data 'Striking' - SunTrustFebruary 27, 2019 11:55 AM Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy TypFebruary 27, 2019 9:01 AM Sarepta Therapeutics (SRPT) Hits Pre-market High, Up 7% with Conference Call OnoingFebruary 27, 2019 8:16 AM